6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-β-D-glucopyranosyl trichloroacetimidate | 133076-40-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-β-D-glucopyranosyl trichloroacetimidate
• 英文别名: |A-D-Glucopyranose, 2-azido-2-deoxy-3,4-bis-O-(phenylmethyl)-, 6-acetate 1-(2,2,2-trichloroethanimidate)；[(2R,3S,4R,5R,6S)-5-azido-3,4-bis(phenylmethoxy)-6-(2,2,2-trichloroethanimidoyl)oxyoxan-2-yl]methyl acetate
• CAS: 133076-40-1
• 化学式: C₂₄H₂₅Cl₃N₄O₆
• 分子量: 571.845
• InChiKey: ZLPSPCBQPLCOIH-LMYCIYFBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-β-D-glucopyranosyl trichloroacetimidate 在 三氟甲磺酸三甲基硅酯 、 4 A molecular sieve 、 sodium methylate 、 sodium hydride 作用下， 以 甲醇 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.75h， 生成 methyl 2-azido-3,4,6-tri-O-benzyl-2-deoxy-α-D-glucopyranosyl-(1->3)-2,4,6-tri-O-benzyl-α-D-glucopyranoside
  参考文献：
  名称：

  α-葡萄糖苷酶抑制剂的合成：曲二糖型假二糖和相关的假三糖11假糖，第38部分：第37部分，请参见参考文献[1]。

  摘要：

  摘要设计并合成了两种曲霉二糖型假二糖和一种三糖，它们含有5-氨基-1,2,3,4-环戊netetrol衍生物或缬氨酸胺，它们通过氮桥与糖残基连接，并作为加工α合成。 -葡糖苷酶I抑制剂。假二糖的合成分别从糖异硫氰酸酯和氨基环糖醇的偶联产物开始，通过用氧化汞（II）环化成环状异脲并随后脱保护来进行。通过保护的瓦伦胺和糖环氧化物的反应，然后脱保护，制备伪假二糖的收率很低。尽管拟低聚糖都是α-葡萄糖苷酶（面包酵母）的强抑制剂，

  DOI：

  10.1016/s0008-6215(98)00045-7
• 作为产物：
  描述：

  thexyldimethylsilyl 6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-β-D-glucopyranoside 在 四丁基氟化铵 、 potassium carbonate 、 溶剂黄146 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 45.0h， 生成 6-O-acetyl-2-azido-3,4-di-O-benzyl-2-deoxy-β-D-glucopyranosyl trichloroacetimidate
  参考文献：
  名称：

  Synthesis of disaccharidic sub-units of a new series of heparin related oligosaccharides

  摘要：

  The chemical synthesis of disaccharides 1 and 2, useful building-blocks for the preparation of a new series of heparin related oligosaccharides containing the unusual sequence (GlcN-IdoA)(n), is described. In addition, the orthogonality of the protective groups would allow access to a wide array of differently sulfated oligosaccharides. As the simplest members of this new class of oligomer, the synthesis of sulfated disaccharides 3 and 4 fully deprotected is reported. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00526-8

文献信息

• [EN] OLIGOSACCHARIDE COMPOUNDS FOR USE IN MOBILISING STEM CELLS<br/>[FR] COMPOSÉS D'OLIGOSACCHARIDE POUR UTILISATION DANS LA MOBILISATION DE CELLULES SOUCHES
  申请人：ENDOTIS PHARMA

  公开号：WO2010029185A1

  公开（公告）日：2010-03-18

  A compound of the following formula or a salt, solvate or formula (I) and a pharmaceutical composition containing said compound. It concerns also its use in the treatment of cancer and/or of pathological angiogenesis and/or in promoting the mobilisation of stem cells, in particular hematopoietic stem cells.

  以下化学式的化合物或盐、溶剂化合物或化学式（I）以及含有该化合物的药物组合物。它还涉及其在治疗癌症和/或病理性血管生成和/或促进干细胞动员，特别是造血干细胞方面的用途。
• Solid- and solution-phase synthesis of heparin and other glycosaminoglycans
  申请人：——

  公开号：US20030013862A1

  公开（公告）日：2003-01-16

  Described is a modular, general synthetic strategy for the preparation in solution and on a solid support of heparin, heparin-like glycosaminoglycans, glycosaminoglycans and non-natural analogs of each of them. Additionally, the modular strategy provides the basis for the preparation of combinatorial libraries and parallel libraries of defined glycosaminoglycan oligosaccharides. The defined glycosaminoglycan structures may be used in high-throughput screening experiments to identify carbohydrate sequences that regulate a host of recognition and signal-transduction processes. The determination of specific sequences involved in receptor binding holds great promise for the development of molecular tools which will allow modulation of processes underlying viral entry, angiogenesis, kidney diseases and diseases of the central nervous system. Notably, the present invention enables the automated synthesis of glycosaminoglycans in much the same fashion that peptides and oligonucleotides are currently assembled.

  描述了一种模块化的通用合成策略，用于在溶液中和固体支撑上制备肝素、类肝素糖胺聚糖、糖胺聚糖以及它们的每一种非天然类似物。此外，该模块化策略为定义的糖胺聚糖寡糖的组合库和平行库的制备提供了基础。定义的糖胺聚糖结构可以用于高通量筛选实验，以识别调节多种识别和信号转导过程的碳水化合物序列。确定参与受体结合的特定序列对于开发分子工具具有巨大的前景，这些工具将允许调节病毒进入、血管生成、肾脏疾病和中枢神经系统疾病等过程。值得注意的是，本发明使得能够以目前组装肽和寡核苷酸的方式自动化合成糖胺聚糖。
• PROCESS FOR PREPARING FONDAPARINUX SODIUM AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF
  申请人：Nadji Sourena

  公开号：US20110105418A1

  公开（公告）日：2011-05-05

  Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.

  描述了合成抗凝血因子Xa的抗凝剂Fondaparinux及其相关化合物的过程。还描述了受保护的五糖中间体，以及通过一系列去保护和磺化反应将受保护的五糖中间体转化为Fondaparinux钠的高效可扩展工业规模生产过程。
• Synthesis of new fluorescently labeled glycosylphosphatidylinositol (GPI) anchors
  作者：Varma Saikam、Riya Raghupathy、Mahipal Yadav、Veeranjaneyulu Gannedi、Parvinder Pal Singh、Naveed A. Qazi、Sanghapal D. Sawant、Ram A. Vishwakarma

  DOI：10.1016/j.tetlet.2011.06.005

  日期：2011.8

  The borondipyrromethene (BODIPY) labeled new glycosylphosphatidylinositol (GPI) molecules were synthesized as cellular probes to study the chemical basis of microdomain organization of GPI-anchored proteins and cholesterol in plasma membrane. The synthesis enabled by a new stereo-selective glycosylation of myo-d-inositol acceptor led to the preparation of optically pure glucosaminyl-(1-6)-α-phosph

  合成了硼联苯二甲亚甲基（BODIPY）标记的新糖基磷脂酰肌醇（GPI）分子作为细胞探针，研究了GPI锚定蛋白质和质膜中胆固醇的微区组织的化学基础。合成能够通过一个新的立体选择性糖基化肌醇- d肌醇受体导致光学纯glucosaminyl-（1-6）-α-磷脂酰的制备肌醇- d肌醇和其非天然立体异构体。
• Synthesis of a 2,3-Di-O-substituted Heptose Structure by Regioselective 3-O-Silylation of a 2-O-Substituted Heptose Derivative
  作者：Kazuyuki Ishii、Yasuaki Esumi、Youhei Iwasaki、Ryohei Yamasaki

  DOI：10.1002/ejoc.200300652

  日期：2004.3

  (Hep), methyl 6,7-di-O-acetyl-2-O-benzyl-L-glycero-α-D-manno-heptopyranoside (3), was treated with both triethylsilyl (TES) and tert-butyldimethylsilyl (TBDMS) chlorides to regioselectively form the 3-O-silyl ethers 4 and 6, respectively. To examine whether silylation of the 3,4-diol of a 2-O-substituted disaccharide also gives the corresponding 3-O-silylated disaccharide, we synthesized α-GlcN3-(1⇄2)-Hep

  2-O-苄基 (Bn) 庚糖 (Hep)、甲基 6,7-二-O-乙酰基-2-O-苄基-L-甘油-α-D-甘露糖-庚糖苷的 3,4-二醇衍生物（ 3)，用三乙基甲硅烷基 (TES) 和叔丁基二甲基甲硅烷基 (TBDMS) 氯化物处理，分别区域选择性地形成 3-O-甲硅烷基醚 4 和 6。为了检查 2-O-取代二糖的 3,4-二醇的甲硅烷基化是否也产生相应的 3-O-甲硅烷基化二糖，我们通过偶联 Hep 2-合成了 α-GlcN3-(1⇄2)-Hep 11a OH 受体 9 与 GlcN3 三氯乙酰亚胺 10. 正如使用 2-O-Bn Hep 3 获得的结果所预期的那样，用 TESCl 处理 α-GlcN3-(1⇄2)-Hep-3,4-二醇 14，然后进行乙酰化仅得到 3-O-TES 15。通过甲硅烷基化/乙酰化（不分离 15）和随后的酸水解，将化合物 14 转化为 3-OH 受体 16。通过将二糖